Добірка наукової літератури з теми "Predicting molecular response in CML"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Predicting molecular response in CML".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Predicting molecular response in CML"
Wolf, Dominik, and Sieghart Sopper. "Molecular response prediction in CML: novel ideas?" Oncotarget 8, no. 46 (September 19, 2017): 80105–6. http://dx.doi.org/10.18632/oncotarget.21049.
Повний текст джерелаWolf, Dominik, and Sieghart Sopper. "Correction: Molecular response prediction in CML: novel ideas?" Oncotarget 9, no. 88 (November 9, 2018): 35871. http://dx.doi.org/10.18632/oncotarget.26360.
Повний текст джерелаAttili, S. V., P. Bapsy, D. Lokanatha, K. Govindababu, J. George, L. A. Jacob, H. K. Dadhich, and G. Anupama. "Are skin reactions a surrogate marker in predicting response to therapy in patients with chronic myeloid leukemia receiving imatinib?" Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 17539. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17539.
Повний текст джерелаHu, Shiwei, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, and Jian Huang. "Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study." Cancers 14, no. 23 (November 23, 2022): 5752. http://dx.doi.org/10.3390/cancers14235752.
Повний текст джерелаGlauche, Ingmar, Christoph Baldow, Sabine Fröhlich, Philipp Schulze, Amit Roy, Milayna Subar, Xiaoning Wang, and Ingo Roeder. "Model-Based Characterization of the Molecular Response Dynamics of Tyrosine Kinase Inhibitor (TKI)-Treated CML Patients – a Comparison of Imatinib and Dasatinib First-Line Therapy." Blood 124, no. 21 (December 6, 2014): 4562. http://dx.doi.org/10.1182/blood.v124.21.4562.4562.
Повний текст джерелаDybko, Jarosław, Bożena Jaźwiec, Olga Haus, Donata Urbaniak-Kujda, Katarzyna Kapelko-Słowik, Tomasz Wróbel, Tomasz Lonc, et al. "The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience." Disease Markers 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/7531472.
Повний текст джерелаBanjar, Haneen R., and Enaam Alsobhi. "Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib." International Scholarly Research Notices 2017 (February 13, 2017): 1–6. http://dx.doi.org/10.1155/2017/1076493.
Повний текст джерелаHaznedaroglu, Ibrahim C. "MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)." Mediterranean Journal of Hematology and Infectious Diseases 6, no. 1 (December 31, 2013): e2014009. http://dx.doi.org/10.4084/mjhid.2014.009.
Повний текст джерелаSopper, Sieghart, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T. Gjertsen, et al. "Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia." Journal of Clinical Oncology 35, no. 2 (January 10, 2017): 175–84. http://dx.doi.org/10.1200/jco.2016.67.0893.
Повний текст джерелаde Lavallade, Hugues, Jane F. Apperley, Jamshid S. Khorashad, Dragana Milojkovic, Alistair G. Reid, Marco Bua, Richard Szydlo, et al. "Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis." Journal of Clinical Oncology 26, no. 20 (July 10, 2008): 3358–63. http://dx.doi.org/10.1200/jco.2007.15.8154.
Повний текст джерелаДисертації з теми "Predicting molecular response in CML"
Glauche, Ingmar, Matthias Kuhn, Christoph Baldow, Philipp Schulze, Tino Rothe, Hendrik Liebscher, Amit Roy, Xiaoning Wang, and Ingo Roeder. "Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison." Macmillan Publishers Limited, part of Springer Nature, 2018. https://tud.qucosa.de/id/qucosa%3A32495.
Повний текст джерелаHöijer, Jonas. "Prognostic Factors for 12 Month Major Molecular Response for Patients with Chronic Myeloid Leukemia." Thesis, Uppsala universitet, Statistiska institutionen, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-201419.
Повний текст джерелаShoeb, Dania. "Factors predicting response to treatment in chronic HCV genotype 3 patients." Thesis, Queen Mary, University of London, 2013. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8450.
Повний текст джерелаHamy, Anne-Sophie. "Identification of Factors Predicting Sensitivity or Resistance to Neoadjuvant Chemotherapy in Breast Cancer Neoadjuvant treatment : the future of patients with breast cancer Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an “option” but an ethical obligation Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status BIRC5 (survivin) : a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort The presence of an in situ component on pre-treatment biopsy is not associated with response to neoadjuvant chemotherapy for breast cancer Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS129.
Повний текст джерелаNeoadjuvant chemotherapy (NAC i.e. chemotherapy before surgery) is increasingly being used for aggressive or locally advanced breast cancer (BCs). Beyond clinical benefits, it represents an opportunity to monitor in vivo sensitivity to treatment. Based on the analysis of datasets of BCs patients treated with NAC, we aimed at identifying mechanisms associated with resistance or sensitivity to treatment.In the first part, we evaluated biological, clinical, pathological and transcriptomic patterns. We demonstrated that unexplored pathological features such as post-NAC lymphovascular invasion may carried an important prognostic information.In a second part, we analyzed impact of imune infiltration in BC and we described extensively the changes of tumor infiltrating lymphocytes (TILs) between pre and post-NAC samples. We showed that the prognostic impact of TILs was different before and after NAC, and was opposite in TNBC and HER2-positive BCs. Finally, we investigated the impact of comedications use during NAC. We found both positive effects - while enhancing immune infiltration and response to treatment - and negative effects with deleterisous oncologic outcomes in specific patients subgroups. In conclusion, the neoadjuvant setting represents a platform to both generate and potentially validate research hypotheses aiming at increasing the efficacy of treatment. The public release of real-life datasets of BC patients treated with NAC would represent a major resource to accelerate BC research
Banjar, Haneen Reda. "Personalized Medicine Support System for Chronic Myeloid Leukemia Patients." Thesis, 2018. http://hdl.handle.net/2440/117837.
Повний текст джерелаThesis (Ph.D.) -- University of Adelaide, School of Computer Science, 2018
McLarty, Kristin. "Molecular Imaging as a Tool for Predicting and Monitoring Response of Breast Cancer to Trastuzumab (Herceptin(R))." Thesis, 2009. http://hdl.handle.net/1807/26471.
Повний текст джерелаChen, Bao-Ju, and 陳寶如. "Molecular Status of EGFR and KRAS Predicting Response to Erlotinib in Non-Small Cell Lung Cancer (NSCLC): a Meta-Analysis." Thesis, 2010. http://ndltd.ncl.edu.tw/handle/62746866968159167964.
Повний текст джерела國防醫學院
生物化學研究所
98
Erlotinib is a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) to treat patients with non-small-cell lung cancer (NSCLC). In previous clinical trials, some biomarkers have been examined, such as EGFR mutation, EGFR gene copy number, EGFR protein expression, and KRAS mutation. But the relationships of these biomarkers and erlotinib were still unclear. Here, we provide a systematic review and meta-analysis to clarify the effect of these biomarkers and the tumor response of erlotinib to patients with NSCLC. We searched PubMed (from 1999 to 2010) on clinical studies of erlotinib to treat NSCLC and extracted tumor response and the molecular status of patients. There is a total of 17 clinical studies, including 3 randomized controlled trials, in NSCLC patients treated with erlotinib 150 mg a day. Patients who harbored EGFR mutation (odds ratio=10.71, CI 95% 5.48-20.91) or EGFR gene copy number gained (odds ratio=2.89, CI 95% 1.17-7.14) have better response to erlotinib. There is no significant difference between EGFR protein expression (odds ratio=1.07, CI 95% 0.55-2.08) and tumor response. And patients who harbored KRAS mutations (odds ratio=0.23, CI 95% 0.10-22.14) have worse response to erlotinib. This is the first study to figure out the effect of EGFR and KRAS molecular status on erlotinib. Before choosing a treatment for NSCLC, tumor EGFR and KRAS should be examined. Patients with EGFR mutations or gene copy number gained should consider using erlotinib first, while patients with KARS mutations should not consider using erlotinib.
Thürigen, Olaf [Verfasser]. "Development of a procedure for genome wide expression profiling from minute Tissue samples and application in mammary carcinoma : gene activity patterns unveiling molecular pathways and predicting clinical response / presented by Olaf Thürigen." 2008. http://d-nb.info/987400517/34.
Повний текст джерелаКниги з теми "Predicting molecular response in CML"
Sherman, Mark E., Melissa A. Troester, Katherine A. Hoadley, and William F. Anderson. Morphological and Molecular Classification of Human Cancer. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0003.
Повний текст джерелаWalsh, Richard A. “Are My Children at Risk, Doctor?”. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190607555.003.0007.
Повний текст джерелаЧастини книг з теми "Predicting molecular response in CML"
Smith, Steven Christopher, and Dan Theodorescu. "Molecular Nomograms for Predicting Prognosis and Treatment Response." In Bladder Tumors:, 165–91. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-928-4_9.
Повний текст джерелаSehl, Mary E., and Max S. Wicha. "Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response." In Methods in Molecular Biology, 333–49. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7493-1_16.
Повний текст джерелаKaira, Kyoichi. "PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer." In Molecular Targeted Therapy of Lung Cancer, 45–61. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-2002-5_3.
Повний текст джерелаWalter, Bernhard, Irmela Schrettenbrunner, Martin Vogelhuber, Jochen Grassinger, Klaus Bross, Jochen Wilke, Thomas Suedhoff, et al. "C-Reactive Protein As a Secretome-Derived Biomarker for Predicting Response to Biomodulatory Therapy in Metastatic Renal Clear Cell Carcinoma." In From Molecular to Modular Tumor Therapy, 353–66. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-9531-2_17.
Повний текст джерелаCrossa, José, Osval Antonio Montesinos-López, Paulino Pérez-Rodríguez, Germano Costa-Neto, Roberto Fritsche-Neto, Rodomiro Ortiz, Johannes W. R. Martini, et al. "Genome and Environment Based Prediction Models and Methods of Complex Traits Incorporating Genotype × Environment Interaction." In Methods in Molecular Biology, 245–83. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2205-6_9.
Повний текст джерелаSingh, Sanjay, Sukanya Tripathy, and Anand Prakash. "Multiple Sclerosis: Molecular Biology, Pathophysiology and Biomarkers." In Neurodegenerative Diseases - Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition), 115–24. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815040913122010010.
Повний текст джерелаPiccart, Martine, Toral Gathani, Dimitrios Zardavas, Hatem A. Azim, Christos Sotiriou, Giuseppe Viale, Emiel J. T. Rutgers, et al. "Cancer of the breast." In Oxford Textbook of Oncology, 546–75. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0043.
Повний текст джерелаТези доповідей конференцій з теми "Predicting molecular response in CML"
Basak, Jayasri, Soma Mukhopadhyay, Sukanta Konar, and Ashis Mukhopadhyay. "Abstract A68: Molecular response of pediatric chronic myeloid leukemia (CML) with imatinib mesylate therapy." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-a68.
Повний текст джерелаArruga, Francesca, Francesca Messa, Monica Pradotto, Roberto Bernardoni, Enrico Bracco, Sonia Carturan, Chiara Maffè, et al. "Abstract 251: Disabled gene is involved in CML progression and its expression level at diagnosis can predict major molecular response (MMR) to imatinib therapy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-251.
Повний текст джерелаChoi, Woonyoung, Debasish Sundi, Michael Metcalfe, i.-ling Lee, Shanna Pretzsch, Jolanta Bondaruk, Elizabeth Plimack, et al. "Abstract 995: Impact of molecular subtypes on predicting chemotherapy response and survival in muscle invasive bladder cancer." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-995.
Повний текст джерелаPeille, Anne-Lise, Armin Maier, Frederic Foucault, Rebekka Krumbach, Tim Kees, Torsten Giesemann, Thomas Metz, Thomas Metcalfe, Heinz-Herbert Fiebig, and Vincent Vuaroqueaux. "Abstract C30: A KRAS pathway activation index predicting response to MEK inhibitors in patient-derived tumor xenografts." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c30.
Повний текст джерелаHadac, Jamie N., Terrah J. Paul Olson, Alyssa A. Leystra, Dawn M. Albrecht, Linda Clipson, Ruth Sullivan, Michael A. Newton, Richard B. Halberg, and William R. Schelman. "Abstract 2356: Characterization of molecular signatures predicting response to 5-FU based chemotherapy in mouse models of colorectal cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2356.
Повний текст джерелаNakashima, Jonathan, and Jantzen Sperry. "Abstract P004: Orthotopic patient-derived xenografts are effective precision oncology models in predicting therapeutic response and acquired drug resistance." In Abstracts: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; October 7-10, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1535-7163.targ-21-p004.
Повний текст джерелаSato, N., M. Wakabayashi, J. Lee, B. Lim, NT Ueno, and H. Ishihara. "Abstract P5-02-06: Predicting the response of molecular targeting agents in triple-negative breast cancer cell lines by kinase activities." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p5-02-06.
Повний текст джерелаVuaroqueaux, Vincent, Hoor Al Hasani, Gerhard Kelter, Hans R. Hendriks, and Heinz-Herbert Fiebig. "Abstract C075: The use of 4HF Cancer Data Miner platform for anin Silicopharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib." In Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-c075.
Повний текст джерелаMakvandi, Mehran, Brian P. Lieberman, Kuiying Xu, Redmond-Craig Anderson, Chenbo Zeng, David A. Mankoff, Daniel A. Pryma, Roger A. Greenberg, and Robert H. Mach. "Abstract C15: Predicting response to PARP inhibitors through quantitative measurements of PARP activity in live BRCA1 mutated cells with a radio-iodinated PARP inhibitor." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-c15.
Повний текст джерелаLinakis, Matthew, James Yates, Eric Masson, and Ganesh Mugundu. "Abstract LB-C14: Using Drug Exposure as a Metric for Predicting Clinical Response to Targeted Cancer Therapeutics from Preclinical Efficacy: A Retrospective Preclinical to Clinical Correlation." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1535-7163.targ-15-lb-c14.
Повний текст джерелаЗвіти організацій з теми "Predicting molecular response in CML"
Shani, Uri, Lynn Dudley, Alon Ben-Gal, Menachem Moshelion, and Yajun Wu. Root Conductance, Root-soil Interface Water Potential, Water and Ion Channel Function, and Tissue Expression Profile as Affected by Environmental Conditions. United States Department of Agriculture, October 2007. http://dx.doi.org/10.32747/2007.7592119.bard.
Повний текст джерела